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The genome of vertebrates contains endogenous
retroviruses (ERVs) that are largely nonfunctional
relicts of ancestral germline infection by exogenous
retroviruses. However, in some mouse strains ERVs
are actively involved in disease. Here we report that
nucleic acid-recognizing Toll-like receptors 3, 7,
and 9 (TLR 3, TLR7, and TLR9) are essential for the
control of ERVs. Loss of TLR7 function caused spon-
taneous retroviral viremia that coincided with the
absence of ERV-specific antibodies. Importantly,
additional TLR3 and TLR9 deficiency led to acute
T cell lymphoblastic leukemia, underscoring a promi-
nent role for TLR3 and TLR9 in surveillance of
ERV-induced tumors. Experimental ERV infection
induced a TLR3-, TLR7-, and TLR9-dependent group
of ‘‘acute-phase’’ genes previously described in HIV
and SIV infections. Our study suggests that in addi-
tion to their role in innate immunity against exoge-
nous pathogens, nucleic acid-recognizing TLRs
contribute to the immune control of activated ERVs
and ERV-induced tumors.
INTRODUCTION
Endogenous retroviruses (ERVs) are germline encoded (Fes-
chotte and Gilbert, 2012), transmitted in a Mendelian fashion,
and account for about 8% of the human and 10% of the
murine genomes, respectively (Stocking and Kozak, 2008).
Besides HIV, the best-studied retroviruses are murine leukemia
viruses (MuLV), which belong to the gammaretroviral genus
and include exogenous (transmitted from one host to another
by infection) and endogenous viruses (Weiss, 2006). MurineIendogenous MuLVs (referred to as ERVs) can undergo complex
recombination events with ecotropic (infecting original host)
and polytropic (infecting a range of hosts) retroviruses, resulting
in spontaneous ERV expression, genomic reintegration, and
subsequent tumor formation (Huebner and Todaro, 1969; Stoye
et al., 1991).
The reactivation and propagation of ERVs is only partially
understood and differs substantially among individual mouse
strains. For example, AKR mice are strongly prone to ERV reac-
tivation, whereas C57BL/6 mice tightly control ERVs (Lowy et al.,
1974). In the latter strain, complex DNA methylation occurs in
waves during development and additional transcriptional control
mechanisms are operational to suppress provirus reactivation
(Rowe and Trono, 2011). The importance of DNA methylation
for the control is highlighted by the observation that the hypo-
morphic DNA-methyltransferase 1 mouse strain (Dnmt1chip/)
succumbs to T cell leukemia, which is in part caused by
deregulated ERVs (Gaudet et al., 2003; Howard et al., 2008).
An additional layer of control is provided by cell-intrinsic mecha-
nisms, e.g., Apobec3 (cytidine deaminase), TRIM5-a (capsid
sensing and blockade of virion uncoating), Tetherin (blocks virus
release), and SAMHD1 (blocks cellular dNTP supply), which
mediate restriction of exogenous and endogenous retroviruses
(Wolf and Goff, 2008; Yan and Chen, 2012).
Innate immune recognition in the cytoplasm or endosome
by pattern recognition receptors such as RIG-I-like receptors
(RLH), AIM2, and Toll-like receptors (TLRs) has been implied in
the control of retrovirus infection (Brennan and Bowie, 2010). In
the endosome, a subset of TLRs (TLR3, TLR7, and TLR9) recog-
nizes nucleic acids such as double-stranded RNA, single-
stranded RNA, and CpG-motive containing DNA, respectively
(Blasius and Beutler, 2010). Of note, recognition of HIV and len-
tiviral vectors are mediated in part by TLR3, TLR7, and TLR9
(Breckpot et al., 2010; Mandl et al., 2008; Yan and Lieberman,
2011). Recent advances additionally revealed that exogenous
infections by Friend-MuLV or MuLV isolated from aged ERV-
prone I/LnJ mice are recognized by the MyD88-TLR7 pathwaymmunity 37, 867–879, November 16, 2012 ª2012 Elsevier Inc. 867
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Control of ERV and ERV-Mediated Tumors by TLRsand lead to antibody-mediated protection (Browne, 2011;
Browne and Littman, 2009; Kane et al., 2011).
However, the role of nucleic acid-recognizing TLRs in the
recognition of ERV and/or immunosurveillance of ERV-induced
malignant transformation has not been investigated. Here we
present the molecular and functional analysis of spontaneously
occurring retroviral reactivation and tumor formation in mice
lacking multiple nucleic acid-recognizing TLRs. We demonstrate
that endogenous retroviruses are expressed and could not
be controlled efficiently by the immune system lacking TLR3,
TLR7, and TLR9. Impairment of ERV-specific antibody re-
sponses in vivo and reduced NK cell priming by DCs in vitro in
the absence of these TLRs suggest that nucleic acid-recognizing
TLRs have an essential function in anti-ERV defense and that
their loss results in late-onset T-ALL formation.
RESULTS
TLR3-, TLR7-, and TLR9-Dependent ERV Viremia
without Immune Activation
To analyze a redundant or synergistic role of the endosomally
located nucleic acid-recognizing TLRs in viral recognition, we
generated TLR3, TLR7, and TLR9 triple-deficient mice (Tlr3/
Tlr7/Tlr9/) by intercrossing single-deficient TLR strains.
Young Tlr3/Tlr7/Tlr9/ mice (6–16 weeks) appear healthy
and were fertile, but at the age of 6–10 months, mice displayed
an increased frequency of moribund appearance. Therefore,
we analyzed the gene expression patterns in the spleen of young
and aged phenotypically normal Tlr3/Tlr7/Tlr9/ mice by
Affymetrix gene expression analysis and compared them to
age-matched wild-type mice (Table S1 available online). Endog-
enous ERV sequences, which have been designatedMela (mela-
noma antigen) (Hayashi et al., 1992), were strongly upregulated
in the absence of all three TLRs (566-fold ± 2-fold for accession
number D10049 and 68.5-fold ± 7.7-fold for accession number
U63133). Of note, ERV mRNA expression correlates with virus
production as shown by the fact that we were able to identify
budding retroviruses by electron microscopy in thymic tissue
of Tlr3/Tlr7/Tlr9/ mice (Figure 1A).
In addition, these results document that in young viremic
Tlr3/Tlr7/Tlr9/mice, no upregulation of innate or adaptive
immune genes or of intrinsic retroviral-restricting genes (e.g.,
Apobec3) are induced. Also, no type I IFN or IFN-induced genes
were detected. Only in the agedmice amoderate increase of two
IFN-dependent genes,Oas1a (2.2-fold) and Irf7 (1.83-fold), could
be observed. These data suggest that in the absence of the
nucleic acid-recognizing TLR3, TLR7, and TLR9, ERVs are spon-
taneously expressed but do not induce generalized immune
activation.
Loss of TLR7 Function Results in ERV Viremia
We then screened Tlr3, Tlr7, and Tlr9 single-, double-, and
triple-deficient mice and Unc93b1-3d mutant mice, which
have a selective deficiency of TLR3, TLR7, and TLR9 function
(Tabeta et al., 2006), for spontaneous ERV gp70-env protein
and gag mRNA expression. Flow cytometry analysis of thy-
mocytes of Tlr7/ (10/16), Tlr3/Tlr7/ (8/9), Tlr7/Tlr9/
(6/7), Tlr3/Tlr7/Tlr9/ (19/19), and Unc93b1-3d (8/8) mice
showed gp70 expression, whereas wild-type C57BL/6 (0/14),868 Immunity 37, 867–879, November 16, 2012 ª2012 Elsevier Inc.Tlr3/(0/6), Tlr9/ (0/6), and Tlr3/Tlr9/ (0/7) thymocytes
did not (Figure 1B). Figure 1C summarizes the ratio of geometric
mean fluorescence intensity of MuLV gp70-env staining versus
control staining. Identical expression patterns were observed
on immune cells from spleen, peripheral blood, and bone
marrow (data not shown). Similarly, gag mRNA was detectable
by RT-PCR in tissue derived from mice with nonfunctional
TLR7 (Figure 1D). Surprisingly, thymocytes and spleen cells
deficient of MyD88 (0/6), a central adaptor in TLR signaling, did
not express gp70 (Figures 1B and 1C), although gag transcripts
were detected (Figure 1D). This observation suggests that
retroviral infection and RNA synthesis take place, but ultimately
that MyD88-mediated signaling may be necessary for retroviral
assembly or propagation (Iannello et al., 2010; Jude et al.,
2003). However, analysis of interferon regulatory factor 3, 5,
and 7 (Irf3, Irf5, and Irf7)-deficient mice (n = 4 each) demon-
strates that only IRF5, a transcription factor activated by TLR7
and TLR9 in conventional DCs (Takaoka et al., 2005), restricted
ERV expression (Figures 1B and 1D). Thus, in independent
mouse strains, which are defective for nucleic acid recognition
or their signaling, ERVs are spontaneously expressed. Although
TLR7 deficiency leads to strong ERV RNA expression, gp70-env
protein can be detected in only 63% of individual mice analyzed,
suggesting that TLR3 and TLR9 may indirectly contribute to ERV
control in vivo.
TLR3, TLR7, andTLR9Expression Pattern in ThymicCell
Subpopulations
ERVs have been shown to infect and be expressed in lympho-
cytes and thymocytes in AKR mice (Deharven, 1964). In order
to better understand the function of endosomal TLRs in protec-
tion against ERVs, we first analyzed their expression in lymphoid
organs, such as spleen and thymus of wild-typemice (Figure 1E).
In line with the known expression pattern of TLR7 and TLR9 in
murine macrophages, dendritic cells (DCs), and B cells as well
as TLR3 in DC subsets andmacrophages, transcripts for all three
TLRs were found in total splenic RNA of wild-type mice. TLR3
and TLR9 are moderately expressed in spleen and weakly in
thymus. TLR7 showed high mRNA expression in both organs.
The dissection of thymocyte subpopulations indicated little ex-
pression of TLR7 in single-positive and double-negative thymo-
cytes and no expression in double-positive (CD4+CD8+) cells.
Analysis of stromal nonthymocyte subsets demonstrated that
cortical thymic epithelial cells (cTECs) and plasmacytoid den-
dritic cells (pDCs) expressed TLR7 (Figure 1E). Thus, T cell-
intrinsic TLR expression is not essential, but cTECs and/or
thymic pDCs are important for ERV control of thymocytes.
TLR3, TLR7, and TLR9 Deficiency Leads to Premature
Death Caused by T Cell Acute Lymphoblastic Leukemia
The presence of ERVs has no apparent influence on the viability
or fertility of the Tlr3/Tlr7/Tlr9/ mice up to 6 months of
age. However, when we autopsied aged mice without apparent
signs of disease for thymic CD4/CD8 ratios or development
of tumors, we found that wild-type, single-deficient (Tlr3/,
Tlr7/, Tlr9/), double-deficient (Tlr3/Tlr7/, Tlr3/Tlr9/,
Tlr7/Tlr9/), and Unc93b1-3d mice showed no abnormali-
ties, whereas 4 out of 16 Tlr3/Tlr7/Tlr9/mice (25%) dis-
played enlarged spleen or thymus and aberrant CD4/CD8 ratios
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Figure 1. ERV Activation in TLR-Deficient Mice
(A) Electron microscopy of ultrathin sections of wild-type (a) and Tlr3-, Tlr7-, Tlr9-deficient (b) thymus; retrovirus-like particles in the process of budding at the
plasma membrane (type C) were detected. Volume density of viral particles was 4.5 ± 1.6 mm3/cm3 (mean value ± standard deviation).
(B) Representative (ERV-)MuLV-gp70 flow cytometry staining (red versus control in blue) of thymic cells derived from C57BL/6 (n = 14), Tlr3/ (n = 6), Tlr7/ (n =
16), Tlr9/ (n = 6), Tlr3/Tlr7/ (n = 9), Tlr3/Tlr9/ (n = 7), Tlr7/Tlr9/ (n = 7), Tlr3/Tlr7/Tlr9/ (n = 19),Myd88/ (n = 6), Irf5/ (n = 4), Irf7/ (n = 4),
and Unc93b1-3d (n = 8) mice were analyzed. Numbers indicate staining positive and total mice analyzed.
(C) Individual flow cytometry stainings of mice from (B) as ratio of geometric mean fluorescence intensity (MFI) of (ERV-)MuLV-gp70 and negative control staining.
(D) Real-time PCR of endogenous retroviral MuLV gag mRNA expression in Tlr3/Tlr7/Tlr9/ (n = 18), C57BL/6 (WT) (n = 5), Tlr3/ (n = 4), Tlr7/ (n = 8),
Tlr9/ (n = 6), Unc93b1-3d (n = 8), Myd88/ (n = 9), Irf7/ (n = 4), and Irf5/ (n = 6) mice. Each dot represents ERV mRNA expression in the spleen of an
individual mouse. Values are relative units (RU) of ERV-specific PCR versus tubulin as housekeeping control. Bars depict mean results for each genotype.
(E) TLR3, TLR7, and TLR9 mRNA expression in spleen, thymus, and thymic subpopulations of C57BL/6 mice. Double-negative (DN) and double-positive (DP)
(CD4 and CD8), cortical thymic epithelial cell (cTEC), medullar TEC, CD8+ cDCs, Sirpa+ cDCs, and plasmacytoid dendritic cell (pDC) were tested for TLR7
expression. Real-time PCR values are relative units (RU) of ERV-specific PCR versus tubulin as housekeeping control. Error bars are standard deviation.
Immunity
Control of ERV and ERV-Mediated Tumors by TLRs(defined as less than 70% CD4/CD8 double-positive thymo-
cytes) (Table 1 and Figure S1A). The resistance of Unc93b1-3d
mice to tumor development, despite their ERV susceptibility,
could be due to a residual TLR3, TLR7, and TLR9 activity (Fig-
ure S1B), which seems to reduce viral load in vivo (Tabeta
et al., 2006) (Figure 1D).
Consequently, 26 out of 30 (87%) aged, visibly sick
Tlr3/Tlr7/Tlr9/mice displayed an enlarged thymus, lymph
nodes, or spleen. In accordance, histology of infiltrated tissue
from sick Tlr3/Tlr7/Tlr9/ mice revealed spontaneous
pre-T cell acute lymphoblastic lymphoma (T-ALL) cells charac-
terized by terminal deoxynucleotidyl transferase (TdT) and CD3
expression (Figure 2A). Flow cytometry further demonstrated
changes in the percentage and distribution of thymocyte sub-
sets. Single CD4+ or CD8+ or CD4-CD8 double-negative T cell
populations dominated in the thymus of sick Tlr3/Tlr7/
Tlr9/ mice and expressed proliferation markers such as
CD44, CD25, and CD71, which are reminiscent of early T-ALLIin humans (Figure 2B; de Leval et al., 2009). In contrast, thymic
T cell subsets of young Tlr3/Tlr7/Tlr9/ mice (between
6 weeks and 6 months of age) were normal (Figure 2B). Overall,
these findings suggest that TLR7 restricts spontaneous ERV
expression in vivo via an IRF5-dependent signaling path-
way. However, spontaneous T-ALL development exclusively
occurred in Tlr3/Tlr7/Tlr9/ mice with increased age and
reduces life expectancy compared to C57BL/6 mice (Figure 2C).
We then isolated and cultured a number of independent tumor
cell lines from individual sick Tlr3/Tlr7/Tlr9/ mice (Table
S2). To demonstrate the oncogenic potential of the T-ALL tumor
cell lines in vivo, we transferred the cell line Baki-1 (ERV positive)
into male mice of different TLR-deficient genotypes. Interest-
ingly, C57BL/6 mice reject the tumor or showed a strongly
delayed susceptibility (Figure 2D and data not shown), whereas
Tlr7/Y, Tlr3/Tlr7/Y, and Tlr3/Tlr7/YTlr9/ mice are in-
creasingly susceptible and succumb to the tumor challenge.
This observation showed that TLR3-, TLR7-, TLR9-deficientmmunity 37, 867–879, November 16, 2012 ª2012 Elsevier Inc. 869
Table 1. T-ALL Incidence in Mice with Different Genotypes
Genotype T-ALL Incidence (n) Average Age (Month)
C57BL/6 0/18 19.32 ± 4.20
Tlr3/ 0/12 12.81 ± 3.44
Tlr7/ 0/17* 14.71 ± 6.03
Tlr9/ 0/12* 17.33 ± 2.15
Tlr3/Tlr7/ 0/14* 14.92 ± 2.56
Tlr3/Tlr9/ 0/14 15.21 ± 3.14
Tlr7/Tlr9/ 0/17 13.24 ± 3.56
Tlr3/Tlr7/Tlr9/ 4/16* 12.56 ± 5.11
Unc93b1-3d 0/17 11.96 ± 1.82
Mice were scored positive by enlarged thymus and aberrant CD4/
CD8 ratio. Asterisk indicates single incidence of CD19-positive B cell
lymphoma. Significance of T-ALL incidence in Tlr3/Tlr7/Tlr9/
versus WT and ERV-expressing Tlr7/, Tlr3/Tlr7/, Tlr7/Tlr9/,
Unc93b1-3d mice was analyzed by the log-rank test: p < 0.05.
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Control of ERV and ERV-Mediated Tumors by TLRstumors are transplantable and indirectly suggests that nucleic
acids from the retrovirus (ssRNA, TLR7 ligand), replication inter-
mediates such as tRNA-priming complex (dsRNA, TLR3 ligand),
or retroviral DNA (TLR9 ligand) could act as innate triggers for an
efficient antitumor immune response.
Spontaneous Expression of Endogenous Retrovirus
To characterize the ERV in more detail, the T-ALL lines (Table S2)
and their supernatants were analyzed by electron microscopy
and biochemical methods. First we identified retroviral particles
by electron microscopy as budding C-type retroviruses (Fig-
ure 3A) and detected reverse transcriptase activity in pelleted
supernatants of Baki-1 cells. Furthermore, tumor cell lines ex-
pressed gag mRNA- and env-gp70 protein (Figures 3B and
3C). Sequence analysis of retroviral RNA derived from purified
virus led to the identification of three closely related sequences
that are homologous to ERVs on chromosomes 8, 1, and 18
of C57BL/6 mice and are annotated as MuLV1, MelARV, or
MuLV-NeRV, respectively (Table S3A; Figure 3D; Li et al.,
1999b; Pothlichet et al., 2006a, 2006b). In line with an
endogenous origin of this retrovirus, matings between Tlr3/
Tlr7+/Tlr9/ ERV-negative mothers and Tlr3/Tlr7/YTlr9/
ERV-positive males resulted in ERV-positive Tlr3/Tlr7/
Tlr9/ offspring, whereas TLR7-competent littermates were
ERV negative (Figure S2). The retroviral isolates were probably
derived from the single-copy ecotropic Emv2 provirus in
C57BL/6 mice, which is defective and replication incompetent
as a result of a mutation in the pol gene at nucleotide 3576
(Li et al., 1999b). A C to G transversion, which restored ERV
replication, was observed in all isolated retroviral sequences
(Figure 3D). Data mining on murine ERVs resulted in the detailed
description of the ERV genetic locus on chromosome 8 (Lee
et al., 2011), which is activated in Tlr3/Tlr7/Tlr9/ mice
(Table S3A). However, it has been suggested that this ERV
is not novel, but is in fact Emv2 (Kozak, 2012). Whether DNA
recombination between ecotropic and polytropic ERVs or se-
quence mutations introduced by ERV restriction mechanisms,
e.g., Aopbec3, lead to primary reactivation of Emv2 needs to
be determined in detail in the future (Jern et al., 2007).870 Immunity 37, 867–879, November 16, 2012 ª2012 Elsevier Inc.Retroviral Integration in Primary Tissue and T-ALL Lines
An essential step in the retroviral life cycle is the manifestation of
retrovirus as provirus in the genomic DNA. Southern blot analysis
utilizing the ERV-locus Emv2-specific probe pEco (Chattopad-
hyay et al., 1980; Kozak, 2012) revealed that C57BL/6 genomic
DNA displays only a single band, whereas all T-ALL cell lines,
which are ofmonoclonal origin (data not shown), showed an indi-
vidual complex pattern with up to five additional bands because
of de novo insertion of the ERVs after recombination with Emv2
(Figure 3E). Similar results were obtained with an ERV-gag-
specific probe (Figures S3A and S3B). As control we used the
C57BL/6-derived EL-4 thymoma (Farrar et al., 1980), but addi-
tional ecotropic bands, without ERV activation (Figures 3B and
3C), were visible.
Of note, retroviral integration is also detected by the pEco
probe in pooled thymic or splenic DNA samples from visibly
healthy Tlr3/Tlr7/Tlr9/ mice (age 4–5 months) but not in
tissue of C57BL/6 mice (Figure 3F; Nexø and Krog, 1977). The
pEco probe identified additional bands with three distinct
patterns in embryos (day 19 p.c.) and nonlymphoid tissue of
adult Tlr3/Tlr7/Tlr9/ mice (Figure S3C). However, adult
Tlr3/Tlr7/Tlr9/ mice did show additional ERV patterns
in lymphoid tissue and ultimately, T-ALL-like tumors had the
most complex band patterns (Figures 3E and 3F). The multipli-
cation of the single ecotropic ERV locus of C57BL/6 in Tlr3/
Tlr7/Tlr9/ embryos, before ERV transcription can be de-
tected (Figure S3D), suggests that new germline reinsertion of
ERVs occurred, which are transmitted to the Tlr3/Tlr7/
Tlr9/ offspring. This observation was in line with data on the
high-virus strain AKR, where germline reinsertions of activated
ERVs have been described (Rowe and Kozak, 1980). However,
the increase in banding pattern complexity in the lymphoid tissue
of adult Tlr3/Tlr7/Tlr9/ mice suggests that clonal out-
growth of preleukemic cells with de novo ERV integrations might
also occur in lymphoid cells. In contrast, samples of splenic or
thymic DNA from Tlr7/ mice and Unc93b1-3d mice showed
a very weak or no additional banding pattern, despite ERV
viremia (Figure 3F).
Thus, all Tlr3/Tlr7/Tlr9/-derived T-ALL tumors, embry-
onic DNA, and thymic and splenic tissue from 4- to 5-month-
old Tlr3/Tlr7/Tlr9/ mice display random and frequent
genomic ERV reintegration. This observation suggests that
recombination events with Emv2 are central to the expression
of a functional highly infective ERV and underscores the joint
role of all three TLRs in the control of ERV-induced tumors and
genome integrity of the germline.
Oncogene Activation because of Retroviral Insertion
Because oncogene activation resulting from insertional muta-
genesis is a well-known mechanism in other models of retroviral
tumor formation (Stoye et al., 1991), we tested the target loci of
the de novo integration in TLR3TLR7TLR9-deficient T-ALL lines
by inverse-PCR. We identified a number of oncogenes (Table
S3B) and characterized the dysregulation of Nup214 and Notch1
in more detail, because they have been described as T cell
tumor-associated oncogenes (Aster et al., 2008; Xu and Powers,
2009) in mice and humans and may explain the predominance
of early T cell tumors (Figures 2A and 2B). In 5% of human
T-ALLs, a chromosome translocation leading to a fusion protein
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Figure 2. Tlr3, Tlr7, and Tlr9 Deficiency Leads to Death Caused by T Cell Acute Lymphoblastic Leukemia
(A) Immunohistology (H&E, TdT, CD3, and CD45RB/B220 staining) of thymus and spleen of diseased tumor-bearing Tlr3/Tlr7/Tlr9/ and C57BL/6 mice at
50-fold magnification. Note that the Tlr3-, Tlr7-, Tlr9-deficient thymus shows a diffuse infiltration of TdT+ tumor cells that reveal a ‘‘starry sky’’ pattern.
(B) Flow cytometry analysis of thymic cell populations in C57BL/6, Tlr3/, young Tlr3/Tlr7/Tlr9/ (<6 months of age), and aged Tlr3/Tlr7/Tlr9/
(8 months to 1.3 years of age) mice 1–3 represent individual sick Tlr3/Tlr7/Tlr9/ mice. Lower histograms depict CD71, CD25, and CD44 staining of the
corresponding mice in the top panel.
(C) Cumulative survival curve of male C57BL/6 (black line; n = 14) and Tlr3/Tlr7/Tlr9/ (red line; n = 21) mice. Statistical analysis with logrank test, p < 0.001.
(D) 750,000 T-ALL (Baki-1) tumor cells, derived from a T-ALL-affected Tlr3/Tlr7/Tlr9/mouse as described in (A) and (B), were injected i.p. into male Tlr7-/Y
(n = 6), Tlr3/Tlr7/Y (n = 6), Tlr3/Tlr7/YTlr9/ (n = 6), and C57BL/6 (n = 8) mice and survival was monitored. Significance of survival was analyzed with the
logrank test: p < 0.001 for WT versus Tlr7/Y, Tlr3/Tlr7/Y, and Tlr3/Tlr7/YTlr9/ mice, respectively, and for Tlr7/Y versus Tlr3/Tlr7/YTlr9/ mice. p <
0.05 for Tlr3/Tlr7/Y versus Tlr3/Tlr7/YTlr9/ mice.
Immunity
Control of ERV and ERV-Mediated Tumors by TLRsof Nup214 and c-Abl has been identified. The fusion protein
consists of a truncated Nup214 that is devoid of the Phe-Gly-
rich (FG) repeat domain (Xu and Powers, 2009). The insertion
of ERV in the tumor cell line Baki-1 into the intron between
exon 16 and 17 of Nup214 (Figure S4) resulted in the loss of
the C-terminal FG repeat. Although the mechanistic function of
truncated Nup214 in oncogenesis is not yet established, we
could demonstrate that protein expression was downregulated
in the virus-targeted tumor lines (detection by C-terminal- and
N-terminal-specific antibodies), despite unchanged mRNA ex-
pression (Figures 3G and 3H). The tumor cell line Teno-4 shows
retroviral reintegration in the last 150 bp of the coding region of
Notch1 and 30 UTR destabilizing AU rich regulatory element
(ARE) (Figure S4; Hodson et al., 2010) leading to a upregulation
of Notch1 mRNA and expression of activated Notch1 (NICD)
(Figures 3G and 3H). Thus, one pathway of T-ALL formation in
Tlr3/Tlr7/Tlr9/mice is caused by de novo DNA integration
of activated ERVs leading to deregulation of T cell-specific onco-
genes in early T cells such as Notch1 and possibly Nup214.
The thymus-specific expression of these oncogenes (Aster
et al., 2008) and the high proliferative rate of thymocytes support
the observation that T-ALL is the dominating tumor in Tlr3/ITlr7/Tlr9/ mice. We have identified two additional retroviral
insertion sites (Table 3SB), but information on the role for
TNKS2 (TRF1-interacting ankyrin-related ADP-ribose poly-
merase 2) and Katnal1 (Katanin p60 ATPase-containing subunit
A- like 1) in tumor formation is scarce.
TLR3-, TLR7-, TLR9-Dependent Induction of Acute-
Phase Proteins upon Acute Retroviral Infection In Vivo
As demonstrated above, spontaneous, chronic retroviral viremia
proceeds without any upregulation of known antiviral immune
response genes in Tlr3/Tlr7/Tlr9/ mice. To examine the
TLR3TLR7TLR9-dependent acute immune response, we in-
fected wild-type mice with purified ERV from Baki-1 cells. The
infection did not induce the expression of IFN-a or IFN response
genes (Figures 4A and 4B), whereas Sendai virus (SeV), a nega-
tive-sense, single-stranded RNA virus of the Paramyxoviridae,
was a strong inducer of IFN-a and of a type I IFN signature
(Figures 4A and 4B, upper half). However, we observed a gene
response upon ERV infection (Figure 4B, lower half) that corre-
lated with the gene expression profiles of simian immunodefi-
ciency virus (SIV)-infected Rhesus macaques (Wiederin et al.,
2010). Of note, 11 out of the 18 upregulated genes after infection,mmunity 37, 867–879, November 16, 2012 ª2012 Elsevier Inc. 871
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Figure 3. Detection of C-type Retrovirus, Sequence Variation, and Retroviral Integration into Oncogenic Loci in T-ALL Tumor Lines
(A) Electron microscopy of ultrathin sections of Baki-1 T-ALL cell line of a Tlr3-, Tlr7-, Tlr9-deficient mouse.
(B) Reverse transcriptase (RT) assay of pelleted supernatant of Baki-1 and EL-4 cells (black bars) and real-time PCR gene expression (gray bars) of ERV gag
mRNA in cell lines of Baki-1, Wuzel-8, and Teno-4 from TLR3TLR7TLR9-deficient mice; controls, EL-4* (T cell lymphoma) and WEHI-231* (B cell lymphoma).
Values are relative units (RU) of ERV-specific PCR versus tubulin PCR as housekeeping control. Error bars are standard deviation.
(C) Env surface staining of EL-4 (control) and Baki-1 cells via env (ERV-)MuLV-specific mAb 83A25 (blue), isotype control (rat-IgG2a) (red), and no primary
antibody (green).
(D) Comparison of partial ERV-pol sequences from Emv-2 (endogenous germline ecotropic MuLV sequence, Chr. 8), MuLV-NeRV (DQ366149.1), MelARV
(DQ366148), AKV (MuLV, locus: MLOCG), and ERVs derived from Tlr3-, Tlr7-, Tlr9-deficient tumors (Baki-1, Teno-4, and Aho-2). Arrows mark sequence
differences. Asterisk marks the C to G change at position 3576, which results in a functional pol gene (Li et al., 1999b).
(E and F) Southern blot analysis of retroviral integration into genomic DNA cut with PvuII of T-ALL cell lines (Baki-1, Aho-2, Wuzel-5, Teno-4, and Mize-8), the
thymoma EL-4 (C57BL/6), WEHI-231 (BALB/c), and (F), splenic or thymic tissue of WT and various TLR-deficient mice. Genomic DNA was pooled: thymus
Tlr3/Tlr7/Tlr9/ (n = 2, age 5 months); spleen Tlr3/Tlr7/Tlr9/ (n = 4, age 4 months); C57BL/6 (n = 4, age 3 months); Tlr7/ (n = 2, age 4.5 months);
Tlr7/Tlr9/ (n = 6, age 9 months); Tlr9/ (n = 2, age 4 months). Unc93b1-3d, individual mouse representative of n = 3.
(G) Real-time PCR of Notch1 (black bars) (triplicates ± SD, n = 2) and Nup214 (gray bars) (representative experiment, n = 2)mRNA expression in tissue and various
cell lines.
(H) Protein blot analysis of active Notch1 and Nup214 protein expression in Tlr3-, Tlr7-, Tlr9-deficient cell lines Teno-4 (ERV integration into the Notch1 and
Nup214), Baki-1 (ERV integration into Nup214), Mize-8 (ERV integration into Nup214), Aho-2, Wuzel-5, and control cell lines WEHI-231, EL-4, and thymus or
spleen. Normalized expression indicates band intensity relative to that of EL-4. b-actin Ab was used as loading control.
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Control of ERV and ERV-Mediated Tumors by TLRssuch as Serpina proteins, apolipoprotein isoforms (Apoa), Fetuin
(Ahsg) family member, Hemopexin (Hpx), and Transthyretin (Ttr),
were identical to genes differentially regulated by SIV and some
of these genes have been characterized as ‘‘acute-phase’’
proteins with anti-HIV function (Wiederin et al., 2010). This
gene induction is TLR3TLR7TLR9 dependent, as shown by the
fact that ERV injection (data not shown) or naturally occurring
retrovirus infection of Tlr3/Tlr7/Tlr9/ mice showed no872 Immunity 37, 867–879, November 16, 2012 ª2012 Elsevier Inc.alteration in gene expression (Table S1). The detection of a
3.15-fold upregulation of the Mela mRNA (accession number
D10049), which is in fact the ERV we used to challenge the
mice with, suggests a successful infection (Figure 4B, green
box). The data suggest that the acute response to an experi-
mental exogenous infection by ERV induces a unique gene
expression profile, which is mainly dependent on nucleic acid-
recognizing TLRs.
AB
Figure 4. ERV-Induced Gene Expression in Wild-Type Mice upon
ERV Infection
(A) IFN-a serum concentrations of mock (PBS), Sendai virus (Cantell strain)
(SeV) (1 3 107 plaque-forming units, PFU), or ERV-Baki-1 (1 3 108 PFU)-in-
fected C57BL/6 wild-type mice (n = 3 per group). Error bars are standard
deviation.
(B) Heat map of gene expression array showing differentially expressed genes
in spleen of SeV, ERV-Baki-1, and mock (PBS)-infected C57BL/6 mice 24 hr
after i.v. infection (mean of n = 3 per group). Mean fold induction (MFI) of genes
differentially expressed in virus-infected versus mock infected mice, corre-
sponding gene abbreviation, and mRNA accession number are given. Upper
half of the panel depicts genes strongly induced by SeV (R9.5-fold), whereas
lower half shows genes strongly induced by ERV-Baki-1 virus (R2.7-fold).
Acute-phase immune response genes identical to genes induced by SIV
infections in Rhesus macaques are boxed in red. Mela D10049 (green box) is
the injected MuLV (ERV-Baki-1 isolate).
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IImpaired Antitumor NK Cell Priming by DCs and DC
Activation in Cells Derived from Tlr3–/–Tlr7–/–Tlr9–/–Mice
To test the hypothesis that TLR3, TLR7, and TLR9 may be
important in the control of retroviral-induced tumor cells, we
analyzed natural killer (NK) cells, which are efficient antitumor
effector cells when primed by TLR-ligand-stimulated DCs (Lucas
et al., 2007). Because the T-ALL cell lines are NK cell targets
in vitro (Figure S5 and Table S2), we tested whether TLR-depen-
dent NK cell priming by nucleic acids derived from Baki-1 cells
is impaired in TLR3TLR7TLR9-deficient DCs. Accordingly, WT
DCs stimulated with Baki-1 DNA or RNAwere able to prime puri-
fied TLR3TLR7TLR9-deficient NK cells to lyse NK cell-sensitive
YAC-1 cells. In contrast, TLR3TLR7TLR9-deficient DCs failed
to prime NK cells (Figure 5A). In vitro stimulation experiments
of Flt3-L-induced DCs further support a role of TLRs in innate
immune recognition of virus or tumor cells because retrovirus
and retroviral RNA led to a TLR7-dependent upregulation of
the activation marker CD40 (Figure 5B) and genomic DNA from
retrovirus-infected organs of Tlr3/Tlr7/Tlr9/mice induced
a TLR9-dependent IFN-a and IL-6 production (Figure 5C). The
distinct impairment of activation of DCs derived from Tlr3/
Tlr7/Tlr9/ mice by RNA and DNA derived from retrovirus
and infected cells, in conjunction, with the resulting lack of NK
cell activation, supports the in vivo observation of tumor suscep-
tibility in Tlr3/Tlr7/Tlr9/ mice.
The Spontaneous ERV Antibody Production Is TLR7
Dependent
In order to demonstrate that the neglect of ERVs by the innate
immune system of Tlr3/Tlr7/Tlr9/mice leads to an altered
adaptive immune response, we first examined the spontaneous,
natural B cell response against ERVs in mice of different geno-
types. We used purified ERVs from Baki-1 cells as antigen for
testing the antibody specificity in mouse sera by ELISA. This
approach is similar to experiments that demonstrated TLR7 is
essential for the induction of a protective adaptive antibody
response against an exogenous experimental Rauscher-like-
MuLV (RL-MuLV) infection (Kane et al., 2011). The key difference
was that we examined untreated mice of different genotypes to
test their unchallenged natural immune response. We isolated
ERVs from Baki-1 cells (Figure 6A) and show that ERV-resistant
Tlr3/, Tlr9/, Tlr3/Tlr9/, and wild-type mice expressed
high amounts of ERV-specific ‘‘natural’’ antibodies (Figure 6B),
whereas the spontaneously ERV-susceptible mouse strains
Tlr7/, Tlr3/Tlr7/, Tlr7/Tlr9/, Tlr3/Tlr7/Tlr9/,
Unc93b1-3d, and Irf5/ completely lacked ERV-specific IgG
antibodies. These results were confirmed by protein blotting
(Figure 6C). Of note, the differences in ERV antigen-pattern
recognition by the natural antibodies suggest that TLR3, TLR9,
and the combination of TLR3 and TLR9 have an active modula-
tory influence on the recognition of ERV or the generation of an
ERV antibody response. In particular it seems that wild-type
mice lack p30gag antibody activity (Figure 6C). To investigate
whether the ERV-specific antibodies were neutralizing, we in-
fected WEHI-231 cells in vitro with GFP-tagged Moloney-
MuLV. The serum from C57BL/6 mice most strongly inhibited
infection, but also serum from Tlr3/Tlr9/ and Tlr9/ mice
had a significantly higher neutralizing capacity than serum
from ERV-expressing Tlr3/Tlr7/Tlr9/, Tlr3/Tlr7/, ormmunity 37, 867–879, November 16, 2012 ª2012 Elsevier Inc. 873
C57BL/6
Tlr9-/-
C
B
me
diu
m
IL-
15
TL
R3
79
-L
Do
tap
DN
A 
RN
A
S
pe
ci
fic
 ly
si
s 
(%
)
0
10
20
30
40
50 NK + WT Flt3-L DC 
NK + Tlr3-/-Tlr7-/-Tlr9-/- Flt3-L DC 
ODN2216 ERV
RNA
ERV SeVThymic
RNA
ce
ll
co
un
t
 %
 o
f m
ax
C5
7B
L/
6
Tl
r7
-/-
Tl
r3
-/-
Tl
r7
-/-
Tl
r9
-/-
CD40
IFN-α [U/ml]
0 2 4 80120
medium
LPS
2216 CpG
WT DNA
Tlr3-/-Tlr7-/-Tlr9-/- DNA
IL-6 [ng/ml]
0,1 0,2 25 50
A
Figure 5. In Vitro Analysis of ERV-TLR Ligand-Associated Immune
Response
(A) Purified Tlr3-, Tlr7-, Tlr9-deficient NK cells were primed with supernatants
from Flt3-L-induced WT (black) or Tlr3-, Tlr7-, Tlr9-deficient (gray) DC cultures
stimulated either with 100 U/ml IL-15 or a mixture of TLR3, TLR7, TLR9 ligands
(5 mg/ml poly(I:C), 0.25 mg/ml R848, 0.25 mM CpG ODN 2216), DNA or RNA
derived from Baki-1 cells, respectively, and subsequently tested for their cyto-
toxic activity with YAC-1 cells as target (effector to target ratio starting at 50:1
withserial 1:1effector dilution).One representativeexperimentsof two is shown.
(B) CD40 upregulation (medium control in blue versus respective stimuli in red)
of in vitro stimulated Flt3-L DCs from C57BL/6, Tlr7/, and Tlr3/Tlr7/
Tlr9/mice. Cells were stimulated with CpG-ODN 2216 (TLR9 ligand), thymic
total RNA, purified ERV, and Sendai virus (SeV).
(C) IL-6 and IFN-a release of in vitro stimulated Flt3-L DCs fromC57BL/6 (black
bars) and Tlr9/ mice (n = 3) (gray bars). Stimuli used were CpG-ODN 2216
(TLR9 ligand), lipopolysaccharide (LPS, TLR4 ligand), and genomic DNA iso-
lated from a thymus of a WT or Tlr3/Tlr7/Tlr9/ mouse. Error bars are
standard deviation.
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Control of ERV and ERV-Mediated Tumors by TLRsTlr7/ mice (Figure 6D). These results complement the in vivo
observation and suggest that a spontaneous protective antibody
response to ERV is triggered in TLR7-competent mice. Therefore874 Immunity 37, 867–879, November 16, 2012 ª2012 Elsevier Inc.TLR7 is the nonredundant, most essential endosomal TLR in the
control of antibody-mediated antiretroviral immune response.
Nevertheless, TLR3 and TLR9 do have a complex modulatory
influence on the TLR7-driven ERV antibody production in vivo.
DISCUSSION
We have identified a role for endosomal nucleic-acid recognizing
TLRs (Blasius and Beutler, 2010) in the immunosurveillance of
endogenous retroviruses (ERVs) and ERV-related tumors in
mice. Of note, loss of TLR7 function in different and independent
mutant mouse strains on a C57BL/6 genetic background
(Tlr7/, Unc93b1-3d, and Irf5/) led to uncontrolled ERV
virema. However, in Tlr3/Tlr7/Tlr9/mice only, viremia pro-
ceeded to acute lymphoblastic T cell lymphoma (T-ALL) forma-
tion because of retroviral reintegration into protooncogenic loci
such as Notch1 and Nup214. Importantly, C57BL/6 mice in
general showed low-level ERV expression and are not prone to
T cell lymphoma (Kozak, 2012; Lowy et al., 1974; Nexø and
Krog, 1977), underscoring the specific effect of the correspond-
ing gene deficiency. Why Unc93b1-3d mutant mice with non-
functional TLR3, TLR7, and TLR9 showed ERV viremia (although
reduced by 1/10th compared to TLR3-, TLR7-, and TLR9-defi-
cient mice) but did not develop T-ALL is currently unknown.
This could be caused by residual TLR3, TLR7, and TLR9 activity
or altered endosomal trafficking (Tabeta et al., 2006), possibly
affecting the transport of retroviral genomic RNA to the plasma
membrane and retroviral budding (Basyuk et al., 2003; Kuang
et al., 2011). Alternatively, other genes apart from TLRs could
be impaired that are needed for promoting viral reintegration.
The preference for T cell lymphoma in Tlr3/Tlr7/Tlr9/
mice is probably due to the high proliferation rate of thymocytes
that are readily infected by ERVs. In line with this hypothesis,
it has been shown in the past that the thymus is critical for infec-
tion and leukemogenesis induced by various exogenous MuLV
strains (Gaulton, 1998). Presumably other non-T cell tumors
could develop in Tlr3/Tlr7/Tlr9/ mice but are not detect-
able because of earlier T-ALL onset and tumor-driven death.
Recently it has been noted that during early embryonic devel-
opment, retrotransposons, including endogenous MuLV, are
derepressed and consequently strongly expressed. They have
a marked influence on the embryonic stem (ES) cell potency
(Macfarlan et al., 2012) and therefore we can not exclude the
possibility that the gene knockout procedure(s), in particular
the ES cell origin of the gene-deficient mice, rather than the
lack of a functional gene, induced theMuLV transcripts. Aspects
of spontaneous ERV activation will be addressed in more detail
in the future, but local demethylation events during development
(Rowe and Trono, 2011) or cellular activation via hormones or
cytokines have been reported to activate LTR (long terminal
repeats) and might play a role in subsequent ERV expression
(Balada et al., 2009). Indeed, Emv2, the only ecotropic ERV in
C57BL/6 on chromosome 8 (Kozak, 2012), which is closely
related to the ERVs emerging in Tlr3/Tlr7/Tlr9/ mice, is
uniquely methylated and strongly expressed in the cerebellum
of normal wild-type C57BL/6 mice (Lee et al., 2011). Further
support for low-level and spontaneous ERV expression comes
from the analysis of WT and Trex1/ mice. Trex1 is a ssDNA-
specific exonuclease and its loss leads to accumulation of
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Figure 6. Spontaneous ERV Antibody Production Is TLR7 Dependent, Modulated by TLR3 and TLR9, and Inhibits Infection In Vitro
(A) Coomassie blue-stained reducing polyacrylamid gel of ERV-isolate. The analysis of the 30 kDa band by protein sequencing confirmed the p30gag ERV identity
(data not shown).
(B) ERV-specific IgG production in unchallenged mice of different genotypes tested by ERV-coated specific ELISA. Statistics t test: *p = 0.0228 for C57BL/6
versus Tlr3/Tlr7/Tlr9/; ***p < 0.0001 for C57BL/6 versus Tlr3/Tlr9/; ***p = 0.0065 for C57BL/6 versus Tlr9/; not significant (*p = 0.3839) for C57BL/6
versus Tlr3/. Genotype (number of mice; average age): Unc93b1-3d (n = 14; 11.0 months); Tlr7/ (n = 16; 6.9 months); Tlr3/Tlr7/(n = 15; 7.5 months);
Tlr7/Tlr9/ (n = 15; 8.0months); Tlr3/Tlr7/Tlr9/ (n = 23; 4.4months); Irf5/ (n = 13; 4.5months); Tlr3/ (n = 13; 3.8months); Tlr9/ (n = 17; 5.9months);
Tlr3/Tlr9/ (n = 28; 4.9 months); C57BL/6 (n = 52; 4.5 months).
(C) Protein blot analysis of ERV-specific IgG production in unchallengedmice of different genotypes, as indicated. ERV consists of p65gag, p30gag, p15gag, p10gag,
p12gag, the Pol encoded proteins p14 (protease), p80 (reverse transcriptase), p46 (integrase), and envelope proteins gp70SU and p15TM. Two lanes on the right
display representative ERV protein loading controls stripes counterstained with Coomassie blue.
(D) In vitro inhibition of GFP-tagged Moloney-MuLV infection of WEHI-231 B cell line by serum from anti-ERV-positive mice. Lower panel shows anti-ERV ELISA
binding activity of the used serum pools from upper panels. Statistics: ***p < 0.0001; ns = not significant; *p = 0.0246 (TLR7 versus TLR9) or *p = 0.0278 (TLR7
versus TLR39) by t test of triplicates. Error bars are standard deviation.
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Control of ERV and ERV-Mediated Tumors by TLRsreverse-transcribed DNA derived from endogenous retroele-
ments, including LTR-containing ERV sequences (Stetson
et al., 2008). This observation suggests that in wild-type cells,
retroelements are activated and transcribed. These elements
could be the target for recombination or mutation processes,
which eventually, but very rarely, lead to the expression of repli-
cation-competent ERVs. Although the exact molecular mecha-
nism of the primary retroviral recombination events is difficult
to analyze in vivo, in vitro recombination experiments support
this hypothesis (Zhang et al., 2000).
Importantly, a constant but low-level ERV activation in wild-
type mice could explain why C57BL/6 mice and other TLR7-
competent strains such as Tlr3Tlr9-, Tlr3-, and Tlr9-deficient
mice produce high ERV-specific IgG-antibody titers. Indeed,
this observation is in line with earlier reports showing a wide-Ispread natural occurrence of high ERV-neutralizing antibody
titers in different wild-type mice (Aaronson and Stephenson,
1974; Ihle et al., 1974). The lack of detectable ERV expression
in C57BL/6 mice is in contrast to results obtained by Kane
et al. (2011) with the mouse strain I/LnJ. In these mice active
ERVs are present and induce ERV-specific antibodies. In
contrast, we observed that all TLR7-impaired mouse strains
(Tlr7/, Tlr3/Tlr7/Tlr9/, Irf5/, and Unc93b1-3d) lack
ERV-specific antibody response but expressed ERVs. This
implies that despite the similarities in pathology and ERV-medi-
ated oncogenesis to the well-studied ERV models, like AKR or
I/LnJ, the impairment of retrovirus control in Tlr3/Tlr7/
Tlr9/ mice is completely different. Our results are consistent
with the finding that TLR7 is essential for a specific B cell re-
sponse against the exogenous Friend-MuLV retrovirus infectionmmunity 37, 867–879, November 16, 2012 ª2012 Elsevier Inc. 875
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Control of ERV and ERV-Mediated Tumors by TLRs(Browne, 2011). In addition, we showed that the natural antibody
response of C57BL/6 mice is able to inhibit infection of a
Moloney-MuLV in vitro. Overall, this observation favors the
model that in all TLR7-competent mice, a sporadic activation
and expression of the ERVs takes place, which drives a protec-
tive TLR7-dependent antibody response. Whether TLR7 on
immune cells, e.g., DCs or cTECs, recognizes the retrovirus
and translates this danger signal into an adaptive antibody
response via B cells or whether B cell-intrinsic TLR7 is important
for the antibody response has to be addressed by cell-specific
TLR7 ablation in the future. The fact that the ERV-specific anti-
bodies present in Tlr3Tlr9 double-deficient and Tlr3 and Tlr9
single-deficient mice vary in their specificity pattern compared
to WT mice and are less protective in vitro suggests that TLR3
and TLR9 do have a modulatory influence on the antibody reper-
toire against ERVs in vivo.
With regard to the innate immune response against retrovi-
ruses, it was recently demonstrated that the defense against
exogenous MuLV infection is not dependent on a functional
type I IFN pathway (Kane et al., 2011). We confirm this finding
and in addition show that an experimental infection of mice
with purified ERV induces a TLR3-, TLR7-, and TLR9-dependent
and rather functionally ill-defined group of acute-phase proteins.
In experimental SIV infection, it was shown that serpina proteins
(alpha 1-antitrypsin) are induced (Wiederin et al., 2010), which in
general have the potential to inhibit retroviral entry (Mu¨nch et al.,
2007). These findings provide new insights into basic antiretrovi-
ral mechanisms, which could translate into better understanding
of HIV innate-immune interactions and furnish new therapeutic
approaches.
We have demonstrated that TLR7 is a key molecule in the
control of ERV viremia. It will be important to analyze the function
of cytoplasmic innate immune receptors (Takeuchi and Akira,
2009) in the control of ERVs because retroviral replication takes
place in the cytoplasm. Degradation of retroviral nucleic acids by
cytosolic exonucleases, e.g., Trex1, might represent a mecha-
nism to efficiently suppress immune activation by innate cyto-
solic receptors (Yan et al., 2010). This could also be related to
the surprising finding that only in Tlr3/Tlr7/Tlr9/ mice
retroviral viremia proceeds to tumor formation because of retro-
viral integration into DNA. Trex1 or other DNA nucleases could
depend on TLR9 activity, and therefore is able to degrade
reverse-transcribed ERV DNA in Tlr7/ before it successfully
integrates. Alternatively, a difference in the capacity to avoid
autointegration could be the cause for higher susceptibility of
Tlr3/Tlr7/Tlr9/ mice to ERV de novo integration in vivo
(Lee and Craigie, 1998). However, the fact that Irf5/ and both
the single and double Tlr7-deficient mice, unlike Tlr3/Tlr7/
Tlr9/ mice, do not succumb to late onset of T-ALL tumors or
manifest a detectable ERV proviral integration supports a model
where the three nucleic acid-recognizing receptors collaborate
to mount a successful antiretroviral and antitumor response
in vivo.
Although antiretroviral and frequently natural antitumor re-
sponses are notoriously weak (Hirsch et al., 2010), we were
able to demonstrate in vitro DC activation by ERV RNA (TLR7-
dependent) and genomic DNA from ERV-viremic Tlr3/Tlr7/
Tlr9/ mice (TLR9-dependent) as well as TLR3-, TLR7-, and
TLR9-dependent NK cell priming by nucleic acid-activated876 Immunity 37, 867–879, November 16, 2012 ª2012 Elsevier Inc.DCs. How TLR3 exerts its function in antitumor response or inhi-
bition of retroviral integration needs to be further investigated,
but its cross priming activity (Schulz et al., 2005) may support
tumor surveillance.
The role of human ERVs (HERV) in disease induction is dis-
cussed very controversially (Kurth and Bannert, 2010). To date,
no replication-competent HERV has been identified in the human
genome, although a successful reconstitution of an infectious
HERV has been demonstrated (Dewannieux et al., 2006). Never-
theless, the proposed use of TLR7- and TLR9-specific inhibitors
as treatment for systemic lupus erythematosus (Barrat and Coff-
man, 2008) could potentially impair the control of HERVs.
Overall, we provide evidence that innate immune activation
through TLRs restricts ERV propagation in vivo and com-
plements cell-intrinsic antiviral immune mechanisms mediated
by (for example) Apobec3 and TRIM5-alpha. Our work further
supports the concept that endosomal nucleic acid-recognizing
TLRs are not only an essential component in the innate
defense against exogenous nonself retroviruses like HIV, but
are as well sensors of nucleic acids derived from ‘‘pathogenic’’
self, like activated germline-encoded ERVs or the tumors they
induce.
EXPERIMENTAL PROCEDURES
Mice and Cell Lines
Mice were handled according to the institutional guidelines. Irf5/ (Takaoka
et al., 2005), Irf7/ (Honda et al., 2005), Myd88/ (Kawai et al., 1999),
Unc93b1-3d/3d (Tabeta et al., 2006), and single TLR3- (Honda et al., 2003),
TLR7- (Hemmi et al., 2002), and TLR9- (Hemmi et al., 2000) deficient mouse
lines have been described previously. Single TLR-deficient mice were back-
crossed from 129Sv to C57BL/6 seven times for TLR7, eight times for TLR3,
and twelve times for TLR9, before they were intercrossed to generate homo-
zygous TLR3-, TLR7-, TLR9-deficient mice. We backcrossed for three more
generations alternating to C57BL/6 and then to Tlr3/Tlr7/Tlr9/ mice to
obtain homozygous Tlr3/Tlr7/Tlr9/ mice, which displayed similar ERV
activation.
We tested the genome contribution with SNP strain-specific genotyping
markers (Harlan, USA) for Tlr3/Tlr7/Tlr9/, Tlr7/, and Tlr3/Tlr7/
mice, which contained 85.5%, 97.9%, and 97.2% of the C57BL/6 genome,
respectively. To exclude a contribution of 129Sv genes, which is an ERV-nega-
tive and low T cell tumor mouse strain (Nexø and Krog, 1977; Risser et al.,
1983), to the ecotropic ERV activation, we first tested 129Sv mice for expres-
sion of ERVs. 9-month-old 129Sv mice (n = 2) showed neither mRNA nor
protein expression (Figures S3D and S4E). In addition, we confirmed the
previously published data that 129Sv does not contain an ecotropic retrovirus
locus by Southern blotting (Figure S3F). Unc93b1-3d/3d mice were obtained
from the Mutant Mouse Regional Resource Centers (MMRRC). All mice were
kept under specific-pathogen-free (SPF) conditions. We generated the tumor
cell lines Baki-1, Aho-2, Teno-4, Mize-8, and Wuzel-5 from individual sick
Tlr3/Tlr7/Tlr9/ mice by culturing lymphoid cells in RPMI/10% FCS.
The T cell lymphoma EL-4 and the B cell lymphoma WEHI-231 were used as
controls.
Histological Analysis, Flow Cytometry Analysis, and Electron
Microscopy
Details for histology, electron microscopy, general flow cytometry, and env-
specific MuLV detection with mAb 83A25 (Evans et al., 1990) are in Supple-
mental Experimental Procedures online.
Real-Time PCR and iPCR
RNA was prepared by Trizol (Invitrogen) extraction, DNase digested (Roche),
and reverse transcribed into cDNA (iScript Kit, BioRad). For TLR expression
studies in whole immune organs and FACS, sorted cells from C57BL/6 mice
Immunity
Control of ERV and ERV-Mediated Tumors by TLRswere prepared. For analysis of nonthymocyte thymic subsets, pools of
young mice were enriched on a percoll-gradient and stained with subset-
specific Abs. In brief, thymocytes were labeled with anti-mouse CD4 (PE)
and CD8a (APC) (BD Biosciences) and sorted with FACSAria (BD) and PCR
was done with a MiniOpticon cycler (BioRad) and the following primers:
Tubulin, 50-CACATCCAGGCCGGACA and 50-TGTTCATCGCTTATGACCTC
CC; TLR-3, 50-CAGGATACTTGATCTCGGCCTT and 50-TGGCCGCTGAGT
TTTTGTTC; TLR-7, 50-CTGGAGTTCAGAGGCAACCATT and 50-GTTATCA
CCGGCTCTCCATAGAA; and TLR-9, 50-AGCTGAACATGAACGGCATCT and
50-TGAGCGTGTACTTGTTGAGCG. Other RT-PCR was done also with
ABsolute SYBR Green mix (Thermo) with the following primers: MuLV-1,
50-GGAGGGGTACGTGGTTCTTT and 50-GCTGGACATCTTCCCAGTGT;
Notch1, 50-CTTATGCCTCAAGGGAACCA and 50-GGGGTTACTGTTGCAC
TCGT; and Nup214, 50-TCGCACATTTTCAAATCAGG and 50-TTTTCCTGC
AAAGTAGGAAGG. Inverse PCR (iPCR) was done as described previously
(Li et al., 1999a); details can be found in the legend of Figure S4.
Reverse Transcriptase Assay
Supernatant of EL-4 or Baki-1 cells was centrifuged at 4,0003 g for 30 min to
remove cellular debris. Virus was pelleted by ultracentrifugation at 100,0003 g
for 1 hr and RT activity was assayed according to the manufacturer’s protocol
(Colorimetric Reverse Transcriptase Kit, Roche, Mannheim).
Gene Expression Profiling
See Supplemental Experimental Procedures online.
In Vitro Stimulation of Flt3-L-Derived BMDC and ELISA
Bone marrow cells of matched C57BL/6, Tlr3/Tlr7/Tlr9/, Tlr7/, and
Tlr9/ mice (all n = 3) were differentiated for 8 days in the presence of Flt3-
L-containing cell supernatant (1:250). Cells were plated at 2.5 3 105 cells/
well in 96-well plates and stimulated overnight with LPS (5 mg/ml), ODN
2216 (0.5 mM), genomic DNA from Tlr3/Tlr7/Tlr9/ and C57BL/6 mice
(2 mg/ml), thymus-RNA from C57BL/6 mice (2 mg/ml), purified ERV-RNA
(2 mg/ml), purified ERV retrovirus from Baki-1-supernatant (MOI 10), and
Sendai virus (Cantell-strain) (MOI 1). Sendai virus was propagated in embryo-
nated 11-day-old chicken eggs. RNA and DNA were complexed with DOTAP
(Roche) according to manufacturer’s instructions. Stimulation with virus took
place in FCS-free RPMI-Medium and after 1 hr incubation FCS was added
(final concentration 10%). Supernatants were collected 18–20 hr later and
analyzed for IL-6 and IFN-a production with ELISA kits by R&D and Axorra,
respectively.
Retrovirus Purification, Cloning, Quantification, and Infection
Retrovirus was isolated from cell-free supernatants of Baki-1, Teno-4, and
Mize-8 after filtration (0.45 mm filter) by ultracentrifugation and saccharose
gradient purification. RNA was isolated and reverse transcribed with a cDNA
kit (Fermentas). cDNA was cloned into pGEM-Teasy vector (Promega). Inserts
between 500 bp and 2 kbp were sequenced and homology to endogenous
retroviruses was identified by Blast search (NCBI). To monitor retroviral infec-
tivity, we used amodifiedMus dunni-based viremia assay to quantitate plasma
probes of mice and supernatants of virus-producing cells. After 3 days, cells
were fixed with ethanol and detection of positive cell foci was performed
with the mAb 83A25, goat anti-rat IgG-peroxidase (Sigma-Aldrich, St. Louis,
MO) as secondary Ab, and AEC-solution (Sigma-Aldrich) as substrate. For
gene array experiments, C57BL/6 mice (n = 3) were infected with 1 3 108
MOI of Baki-1-purified ERV in 100 ml PBS i.v. After 24 hr, mice were sacrificed
and RNA was isolated from spleen. For serum inhibition test in vitro, we spin-
infected WEHI-234 B cells with MuLV ZAP, which is Moloney-MuLV with GFP
(Shoemaker et al., 1981). In brief, 5 3 105 cells were incubated in 500 ml with
17.53 106 IU/ml ZAP virus.We added serum frompools of different genotypes
at a 1:50 dilution, centrifuged for 90 min at 400 3 g at 32C, incubated over-
night, and measured the percent GFP-positive cells.
Southern Hybridization Analysis and Protein Blotting
Detailed procedures are in Supplemental Experimental Procedures online.
In Vitro Assays for NK Cell Priming
See Supplemental Experimental Procedures online.ISUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.immuni.2012.07.018.
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